vertex journavx suzetrigine

Vertex, Journavx and FDA

Scientific American · 3d

What Is Journavx, the New Opioid-Free Painkiller from Vertex?

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment

Bloomberg on MSN · 3d

New pain drug, Vertex’s Journavx, gets FDA approval as safer alternative to addictive opioids

Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, surgeries, and other injuries and procedures.

BioSpace · 3d

FDA Approves Vertex’s Journavx as First New Pain Drug in Decades

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum in the fledgling non-opioid pain space.

AFP3d

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

18h

Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming ...

14hon MSN

Vertex stock price target raised to $550 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results